| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Selling, general, and administrative | NaN | NaN | NaN | 43,612 |
| Total revenue | 139,514 | 147,139 | 70,445 | 239,240 |
| Cost of sales | 30,695 | 22,104 | 21,496 | 15,325 |
| Research and development | 95,472 | 75,876 | 98,274 | 79,233 |
| Selling, general, and administrative | 28,777 | 62,514* | 31,655 | NaN |
| Impairment of assets held for sale | NaN | -27,585* | 97,038 | NaN |
| Total expenses | 154,944 | 132,909 | 248,463 | 138,170 |
| Income (loss) from operations | -15,430 | 14,230 | -178,018 | 101,070 |
| Interest expense | 4,901 | 5,824 | 5,482 | 5,518 |
| Gain on debt extinguishment | NaN | 0* | -28,714 | NaN |
| Gain on disposition of novavax cz assets | NaN | 0* | NaN | NaN |
| Other income, net | 11,825 | 9,497 | 9,178 | 11,902 |
| Income (loss) before income tax expense | -8,506 | 17,903 | -203,036 | 107,454 |
| Income tax expense | 985 | 376 | -657 | 946 |
| Net income (loss) | -9,491 | 17,527 | -202,379 | 106,508 |
| Basic EPS | -0.06 | 0.108 | -1.25 | 0.66 |
| Diluted EPS | -0.06 | 0.1 | -1.25 | 0.62 |
| Basic Average Shares | 163,276,000 | 162,543,000 | 162,353,000 | 162,019,000 |
| Diluted Average Shares | 163,276,000 | 175,219,000 | 162,353,000 | 177,215,000 |
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)